Description: Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australasia, North America, Europe, Asia, India, and internationally. The company offers pharma generics, including tablets, hard and soft gelatin capsules, sachets, oral liquids, and powders, as well as semi solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Clavicin, Combiart, Solcer, Melonax, Duotab, and Vitafer brands; and drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was founded in 1990 and is headquartered in Bengaluru, India.
Home Page: www.strides.com
Officers
| Name | Title |
|---|---|
| Mr. Arun Kumar Pillai B.Com. | Founder & Non-Exec. Chairman |
| Dr. R. Ananthanarayanan | CEO, MD & Director |
| Mr. Badree Komandur | Group CFO, Exec. Director of Fin. & Exec. Director |
| Ms. Manjula Ramamurthy | Compliance Officer & Company Sec. |
| Mr. A. Lakshmi Narayanan | Chief Information Technology Officer |
Exchange: BSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 22.0538 |
| Price-to-Book MRQ: | 1.4095 |
| Price-to-Sales TTM: | 0.9481 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |